Skip to main content
Erschienen in: Medical Oncology 4/2014

01.04.2014 | Original Paper

Evaluation of histidine-rich glycoprotein tissue RNA and serum protein as novel markers for breast cancer

verfasst von: Marwa Matboli, Sanaa Eissa, Hebatallah Said

Erschienen in: Medical Oncology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Advances in the field of breast cancer (BC) biomarkers discovery facilitate diagnosis and treatment of BC in its pre-invasive state. While the genetic tissue markers are making significant advances in understanding the molecular basis of BC, serum has long been considered a rich source for biomarkers. So, integrated genomic and proteomic strategies play a huge role in the analytical validation of BC biomarkers and represent a true milestone in the areas of diagnostics and personalized medicine. This study included 60 cases (BC), 30 patients with fibroadenoma and 30 healthy women. Histidine-rich glycoprotein RNA (HRG) tissue expression was analyzed through gene expression-based outcome for breast cancer online algorithm (GOBO) bioinformatic analysis. To confirm our informatics analysis, HRG RNA was detected in breast tissue samples by RT-PCR, and HRG serum protein was estimated by ELISA. GOBO analysis revealed increased HRG RNA expression in all subtypes of BC with relative higher expression in basal subtype and grade 2. We confirmed these findings by HRG tissue RNA with 71.7 % sensitivity and 93.3 % specificity. HRG serum protein was 86.7 % sensitivity and 80 % specificity. HRG tissue RNA and serum protein could be considered as promising novel markers for prediction of BC prognosis.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Cancer incidence and mortality worldwide: IARC cancer base no. 10. Lyon: International Agency for Research on Cancer; 2012. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Cancer incidence and mortality worldwide: IARC cancer base no. 10. Lyon: International Agency for Research on Cancer; 2012.
2.
Zurück zum Zitat Misek DE, Kim EH. Protein biomarkers for the early detection of breast cancer. Int J Proteomics. 2011;2011:343582. Misek DE, Kim EH. Protein biomarkers for the early detection of breast cancer. Int J Proteomics. 2011;2011:343582.
3.
Zurück zum Zitat Cecchini RS, Costantino JP, Cauley JA, Cronin WM. Body mass index and the risk for developing invasive breast cancer among high-risk women in NSABP P-1 and STAR breast cancer prevention trials. Cancer Prev Res. 2012;5(4):583–92.CrossRef Cecchini RS, Costantino JP, Cauley JA, Cronin WM. Body mass index and the risk for developing invasive breast cancer among high-risk women in NSABP P-1 and STAR breast cancer prevention trials. Cancer Prev Res. 2012;5(4):583–92.CrossRef
5.
Zurück zum Zitat Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumors. Nature. 2000;406(6797):747–52.PubMedCrossRef Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumors. Nature. 2000;406(6797):747–52.PubMedCrossRef
6.
Zurück zum Zitat Slamon D, Leyland-Jones B, Shak S, et al. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: a randomized, multinational controlled phase III trial. Presented at: 34th annual meeting of the American Society of Clinical Oncology; May 16–19, 1998. Los Angeles, CA. Abstract 377. Slamon D, Leyland-Jones B, Shak S, et al. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: a randomized, multinational controlled phase III trial. Presented at: 34th annual meeting of the American Society of Clinical Oncology; May 16–19, 1998. Los Angeles, CA. Abstract 377.
7.
Zurück zum Zitat Herceptin [prescribing information]. South San Francisco, CA: Genentech, Inc; 2010. Herceptin [prescribing information]. South San Francisco, CA: Genentech, Inc; 2010.
8.
Zurück zum Zitat Schaub NP, Jones KJ, Nyalwidhe JO, Cazares LH, Karbassi ID, Semmes OJ. Serum proteomic biomarker discovery reflective of stage and obesity in breast cancer patients. J Am Coll Surg. 2009;208(5):970–8.PubMedCrossRef Schaub NP, Jones KJ, Nyalwidhe JO, Cazares LH, Karbassi ID, Semmes OJ. Serum proteomic biomarker discovery reflective of stage and obesity in breast cancer patients. J Am Coll Surg. 2009;208(5):970–8.PubMedCrossRef
9.
Zurück zum Zitat Thulin A. Role of histidine-rich glycoprotein in angiogenesis and tumor growth. Acta Universtatis Upsaliensis. Digital Comprehensive summaries of Uppsala Dissertation from faculty of medicine 505.63 pp. Uppsala; 2009. ISBN-978-91-554-7674-8. Thulin A. Role of histidine-rich glycoprotein in angiogenesis and tumor growth. Acta Universtatis Upsaliensis. Digital Comprehensive summaries of Uppsala Dissertation from faculty of medicine 505.63 pp. Uppsala; 2009. ISBN-978-91-554-7674-8.
10.
Zurück zum Zitat Jain S, Zuka M, Liu J, et al. Platelet glycoprotein Ib alpha supports experimental lung metastasis. Proc Natl Acad Sci USA. 2010;104(21):9024–8.CrossRef Jain S, Zuka M, Liu J, et al. Platelet glycoprotein Ib alpha supports experimental lung metastasis. Proc Natl Acad Sci USA. 2010;104(21):9024–8.CrossRef
11.
Zurück zum Zitat Carey LA. Molecular intrinsic subtypes of breast cancer. In Hayes DF, Dizon DS, editors. Up to date. Waltham, MA: Up To Date; 2012. Carey LA. Molecular intrinsic subtypes of breast cancer. In Hayes DF, Dizon DS, editors. Up to date. Waltham, MA: Up To Date; 2012.
12.
Zurück zum Zitat Pinder SE, Elston CW, Ellis IO. In Invasive carcinoma: usual histological types. 3rd ed. In: Elston CW, Ellis IO, editors. The breast. Edinburgh: Churchill Livingstone; 1998. p. 283–337. Pinder SE, Elston CW, Ellis IO. In Invasive carcinoma: usual histological types. 3rd ed. In: Elston CW, Ellis IO, editors. The breast. Edinburgh: Churchill Livingstone; 1998. p. 283–337.
13.
Zurück zum Zitat Sobin L, Gospodarowicz M, Wittekind C, editors. TNM classification of malignant tumors. 7th ed. Hoboken, NJ: Wiley; 2009. Sobin L, Gospodarowicz M, Wittekind C, editors. TNM classification of malignant tumors. 7th ed. Hoboken, NJ: Wiley; 2009.
14.
Zurück zum Zitat World Health Organization. International histological classification of tumours. 2nd ed. Geneva: World Health Organization, 1969–1981. Berlin: Springer; 1988. Present. World Health Organization. International histological classification of tumours. 2nd ed. Geneva: World Health Organization, 1969–1981. Berlin: Springer; 1988. Present.
15.
Zurück zum Zitat Hummon AB, Lim SR, Difilippantonio MJ, Ried T. Isolation and solubilization of proteins after TRIzol® extraction of RNA and DNA from patient material following prolonged storage. Biotech J. 2007;42:467–72.CrossRef Hummon AB, Lim SR, Difilippantonio MJ, Ried T. Isolation and solubilization of proteins after TRIzol® extraction of RNA and DNA from patient material following prolonged storage. Biotech J. 2007;42:467–72.CrossRef
16.
Zurück zum Zitat Koide T, Foster D, Yoshitake S, Davie EW. Amino acid sequence of human histidine rich glycoprotein derived from the nucleotide sequence of its cDNA. Biochem J. 1986;25:2220–5.CrossRef Koide T, Foster D, Yoshitake S, Davie EW. Amino acid sequence of human histidine rich glycoprotein derived from the nucleotide sequence of its cDNA. Biochem J. 1986;25:2220–5.CrossRef
17.
Zurück zum Zitat Sabbatini ARM, Battolla MB, Martini PE, Ranieri-Raggi DM, Moir AJG, Raggi A. Evidence that muscle cells do not express the histidine-rich glycoprotein associated with AMP deaminase but can internalise the plasma protein. Eur J Histochem. 2011;55(1):e6. doi:10.4081/ejh.2011.e6.PubMedCentralPubMed Sabbatini ARM, Battolla MB, Martini PE, Ranieri-Raggi DM, Moir AJG, Raggi A. Evidence that muscle cells do not express the histidine-rich glycoprotein associated with AMP deaminase but can internalise the plasma protein. Eur J Histochem. 2011;55(1):e6. doi:10.​4081/​ejh.​2011.​e6.PubMedCentralPubMed
18.
Zurück zum Zitat Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Altieri DC. Urine detection of survivin and diagnosis of breast cancer. JAMA J. 2001;285(3):324–8.CrossRef Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Altieri DC. Urine detection of survivin and diagnosis of breast cancer. JAMA J. 2001;285(3):324–8.CrossRef
19.
Zurück zum Zitat Zweig MH, Campbell G. Receiver operating characteristic (ROC) Plots, a fundamental evaluation tool in clinical medicine. Clin Chem J. 1993;39(4):561–77. Zweig MH, Campbell G. Receiver operating characteristic (ROC) Plots, a fundamental evaluation tool in clinical medicine. Clin Chem J. 1993;39(4):561–77.
20.
Zurück zum Zitat Ringner M, Fredlund E, Hakkinen J, Borg A, Staaf J. GOBO: gene expression-based outcome for breast cancer online. PLoS One J. 2011;6:e17911.CrossRef Ringner M, Fredlund E, Hakkinen J, Borg A, Staaf J. GOBO: gene expression-based outcome for breast cancer online. PLoS One J. 2011;6:e17911.CrossRef
21.
Zurück zum Zitat Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nat J. 2000;406:747–52.CrossRef Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nat J. 2000;406:747–52.CrossRef
22.
Zurück zum Zitat Eissa S, Swellam M, Ismail M, Hamdy M, Mokhtar N. Emerging role of p53, bcl-2 and telomerase activity in Egyptian breast cancer patients. IUBMB Life J. 2004;56(8):483–90.CrossRef Eissa S, Swellam M, Ismail M, Hamdy M, Mokhtar N. Emerging role of p53, bcl-2 and telomerase activity in Egyptian breast cancer patients. IUBMB Life J. 2004;56(8):483–90.CrossRef
23.
Zurück zum Zitat Thulin A, Ringvall M, Dimberg A, et al. Activated platelets provide a functional microenvironment for the antiangiogenic fragment of histidine-rich glycoprotein. Mol Cancer Res J. 2009;7(11):1792–802.CrossRef Thulin A, Ringvall M, Dimberg A, et al. Activated platelets provide a functional microenvironment for the antiangiogenic fragment of histidine-rich glycoprotein. Mol Cancer Res J. 2009;7(11):1792–802.CrossRef
24.
Zurück zum Zitat Klenotic PA, Huang P, Palomo J. Histidine-rich glycoprotein modulates the anti-angiogenic effects of vasculostatin. Am J Pathol. 2010;176(4):2039–50.PubMedCentralPubMedCrossRef Klenotic PA, Huang P, Palomo J. Histidine-rich glycoprotein modulates the anti-angiogenic effects of vasculostatin. Am J Pathol. 2010;176(4):2039–50.PubMedCentralPubMedCrossRef
25.
Zurück zum Zitat Saigo K, Yoshida A, Sugano W, Ryo R, Yamaguchi N. Histidine-rich glycoprotein in blood during inflammation, surgical operation or hemodialysis. Rinsho Ketsueki. 1990;31(12):1914–9.PubMed Saigo K, Yoshida A, Sugano W, Ryo R, Yamaguchi N. Histidine-rich glycoprotein in blood during inflammation, surgical operation or hemodialysis. Rinsho Ketsueki. 1990;31(12):1914–9.PubMed
26.
Zurück zum Zitat Menga R, Gormleya M, Vadiraja B, Rosenbergc BA, Quonga AA. Low abundance protein enrichment for discovery of candidate plasma protein biomarkers for early detection of breast cancer. J Proteomics. 2011;1(75):366–74.CrossRef Menga R, Gormleya M, Vadiraja B, Rosenbergc BA, Quonga AA. Low abundance protein enrichment for discovery of candidate plasma protein biomarkers for early detection of breast cancer. J Proteomics. 2011;1(75):366–74.CrossRef
27.
Zurück zum Zitat Reeves GK, Beral V, Green J, Gathani T, Bull D. Hormonal therapy for menopause and breast cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol J. 2006;7:910–8.CrossRef Reeves GK, Beral V, Green J, Gathani T, Bull D. Hormonal therapy for menopause and breast cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol J. 2006;7:910–8.CrossRef
28.
Zurück zum Zitat DeMaat MPM, Kameling SWA, Kluft C. The sensitivity and specificity of some clotting rate and immunological fibrinogen assays for high, low and low molecular weight forms of fibrinogen. In: DeMaat MPM, editor. Regulation and modulation of the plasma fibrinogen level. Rotterdam: University of Rotterdam. Thesis; 1995. pp. 47–59. DeMaat MPM, Kameling SWA, Kluft C. The sensitivity and specificity of some clotting rate and immunological fibrinogen assays for high, low and low molecular weight forms of fibrinogen. In: DeMaat MPM, editor. Regulation and modulation of the plasma fibrinogen level. Rotterdam: University of Rotterdam. Thesis; 1995. pp. 47–59.
29.
Zurück zum Zitat Rohleder N, Wolf JM, Piel M, Kirschbaum C. Impact of oral contraceptive use on glucocorticoid sensitivity of pro-inflammatory cytokine production after psychosocial stress. Psychoneuroendocrinology. 2003;28(3):261–73.PubMedCrossRef Rohleder N, Wolf JM, Piel M, Kirschbaum C. Impact of oral contraceptive use on glucocorticoid sensitivity of pro-inflammatory cytokine production after psychosocial stress. Psychoneuroendocrinology. 2003;28(3):261–73.PubMedCrossRef
30.
Zurück zum Zitat Schwanhausser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, Chen W, Selbach M. Global quantification of mammalian gene expression control. Nature. 2011;473(7347):337–42.PubMedCrossRef Schwanhausser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, Chen W, Selbach M. Global quantification of mammalian gene expression control. Nature. 2011;473(7347):337–42.PubMedCrossRef
31.
Zurück zum Zitat Shebl F, Pinto LA, Garcia-Pineres A, Lempicki R, Williams M, Harro C, Hildesheim A. Comparison of mRNA and protein measures of cytokines following vaccination with human papillomavirus-16 L1 virus-like particles. Cancer Epidemiol Biomarkers Prev. 2010;19(4):978–81.PubMedCentralPubMedCrossRef Shebl F, Pinto LA, Garcia-Pineres A, Lempicki R, Williams M, Harro C, Hildesheim A. Comparison of mRNA and protein measures of cytokines following vaccination with human papillomavirus-16 L1 virus-like particles. Cancer Epidemiol Biomarkers Prev. 2010;19(4):978–81.PubMedCentralPubMedCrossRef
Metadaten
Titel
Evaluation of histidine-rich glycoprotein tissue RNA and serum protein as novel markers for breast cancer
verfasst von
Marwa Matboli
Sanaa Eissa
Hebatallah Said
Publikationsdatum
01.04.2014
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 4/2014
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0897-4

Weitere Artikel der Ausgabe 4/2014

Medical Oncology 4/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.